FormWeb • ARIPiprazole

Oregon Department of Corrections

Approved Formulary

Webpage Links

Add Formweb to your mobile device

Android iOS

February P&T meeting minutes have been posted.

Oregon Department of Corrections

Approved Formulary

Search results for:

ARIPiprazole

ARIPiprazole

Therapeutic Substitutions Aripiprazole Long-Acting Injectables
Cell Status NFISA
Exceptions / Designators Formulary restricted to oral tablets only. Long-acting injectables are non-formulary.

Brand names: ABILIFY, ABILIFY MAINTENA

Form	Strength
SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR	300 mg; 400 mg
TABLET, ORAL	2mg; 5mg; 10mg; 15mg; 20mg; 30mg

Additional Information:

NOTE: For information specific to Aristada, please see the other aripiprazole lauroxil listing.

SEPTEMBER 2023 P&T MINUTES

JULY 2023 P&T MINUTES

JANUARY 2021 P&T MINUTES

OCTOBER 2018 P&T MINUTES

NOVEMBER 2016 P&T MINUTES

AUGUST 2016 P&T MINUTES

JULY 2016 P&T MINUTES

NOVEMBER 2015 P&T MINUTES

SEPTEMBER 2013 P&T MINUTES

NOVEMBER 2011 P&T MINUTES

OCTOBER 2011 P&T MINUTES

SEPTEMBER 2011 P&T MINUTES

AUGUST 2011 P&T MINUTES

JULY 2011 P&T MINUTES

JUNE 2011 P&T MINUTES

MARCH 2011 P&T MINUTES

JANUARY 2011 P&T MINUTES

Last updated: Apr. 29, 2024

Black Box Warning: Elderly patients with dementia related psychosis
FDA Drug Safety: Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns

This site is intended for the staff of Oregon Department of Corrections.
While others may view accessible pages, Oregon Department of Corrections makes no warranty, express or implied,
as to the use of this information outside of Oregon Department of Corrections.